Lonza renforce son site de Viège.

The Actulabo newspaper reports that Lonza is strengthening its bioconjugation capabilities at the Ibex Biopark in Visp, Switzerland, with two extensions. The first involves the construction of a new 800 m² bioconjugation suite for a biopharmaceutical client, generating around a hundred jobs and becoming operational in 2027. The second extension plans for two versatile bioconjugation rooms of 2,000 m² by 2028, creating 200 jobs and doubling Lonza's production capacities. [Extracted from the article]

Le journal Actulabo rapporte que Lonza renforce ses capacités de bioconjugaison à l'Ibex Biopark de Viège, en Suisse, avec deux extensions. La première consiste en la construction d'une nouvelle suite de bioconjugaison de 800 m² pour un client biopharmaceutique, générant une centaine d'emplois et opérationnelle en 2027. La seconde extension prévoit deux salles de bioconjugaison polyvalentes de 2 000 m² pour 2028, créant 200 emplois et doublant les capacités de production de Lonza. [Extracted from the article]

Copyright of Actulabo is the property of MCM Presse and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)